{
    "clinical_study": {
        "@rank": "10", 
        "arm_group": [
            {
                "arm_group_label": "PTH", 
                "arm_group_type": "Experimental", 
                "description": "Human parathyroid hormone [hPTH-(1-34)]"
            }, 
            {
                "arm_group_label": "ALN", 
                "arm_group_type": "Active Comparator", 
                "description": "Alendronate"
            }, 
            {
                "arm_group_label": "PTH+ALN", 
                "arm_group_type": "Experimental", 
                "description": "Human parathyroid hormone [hPTH-(1-34)] plus alendronate"
            }
        ], 
        "brief_summary": {
            "textblock": "This study looks at the effects of two medications, alendronate and parathyroid hormone, on\n      bone mass and on bone formation and bone breakdown in women with osteoporosis. We will\n      randomly select postmenopausal women who have osteoporosis to receive laboratory-produced\n      human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants\n      will return to the study center periodically to have their bone mass measured and to give\n      blood and urine samples for tests of bone formation and breakdown and for other laboratory\n      tests.  Those who complete the study are eligible for one or two 12 month extension studies."
        }, 
        "brief_title": "Alendronate and/or Parathyroid Hormone for Osteoporosis", 
        "completion_date": {
            "#text": "June 2006", 
            "@type": "Actual"
        }, 
        "condition": "Osteoporosis", 
        "condition_browse": {
            "mesh_term": "Osteoporosis"
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, prospective, open-label study in which osteoporotic postmenopausal\n      women self-administer synthetic hPTH-(1-34), alendronate, or both, every day for 2.5 years.\n      Participants initially come to Massachusetts General Hospital once a month, and subsequently\n      once every 3-6 months, for measurements of serum and urine indices of bone formation and\n      resorption, serum and urine toxicity tests, and DXA/QCT measurements of bone mass. One-third\n      of the participants take hPTH-(1-34) daily, one-third take alendronate once daily, and\n      one-third take both daily (Phase A, months 0-30).\n\n      Participants who complete Phase A are eligible for a 12 month extension study (Phase B,\n      months 30-42), during which any alendronate treatment is continued without change and any\n      hPTH 1-34 treatment is stopped.\n\n      Participants who complete Phase B are eligible for a second 12 month extension study (Phase\n      C, months 42-54), during which any alendronate treatment is continued without change and\n      every participant takes hPTH 1-34.\n\n      During Phases B and C, these participants come to Massachusetts General Hospital once every\n      6 months for measurements of serum and urine indices of bone formation and resorption, serum\n      and urine toxicity tests, and DXA/QCT measurements of bone mass."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Lumbar spine or hip BMD T-score less than or equal to minus 2.0\n\n          -  Postmenopausal at least 5 years\n\n          -  Fully ambulatory\n\n          -  Able to give informed consent\n\n        Exclusion Criteria:\n\n          -  No concurrent illnesses that cause bone loss\n\n          -  No recent drug treatment for osteoporosis\n\n          -  No recent fracture"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "176", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000400", 
            "org_study_id": "P50 AR44855 NIAMS-023", 
            "secondary_id": "P50AR044855"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PTH", 
                    "PTH+ALN"
                ], 
                "description": "37 mcg once daily by self-administered sc injection", 
                "intervention_name": "Human parathyroid hormone [hPTH-(1-34)]", 
                "intervention_type": "Drug", 
                "other_name": "teriparatide"
            }, 
            {
                "arm_group_label": [
                    "ALN", 
                    "PTH+ALN"
                ], 
                "description": "70 mg/week by oral route", 
                "intervention_name": "alendronate", 
                "intervention_type": "Drug", 
                "other_name": "Fosamax"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hormones", 
                "Alendronate", 
                "Teriparatide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Osteoporosis", 
            "Bone formation", 
            "Bone resorption", 
            "Parathyroid hormone (PTH)", 
            "Postmenopause"
        ], 
        "lastchanged_date": "December 6, 2013", 
        "link": {
            "description": "Click here for more information about this study.", 
            "url": "http://www.mgh.harvard.edu"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Bone Formation-Resorption Coupling and Osteoporosis", 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Robert M. Neer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "change in spine bone mineral density", 
            "safety_issue": "No", 
            "time_frame": "study months 30 (phase A), 42 (phase B), 54 (phase C)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000400"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Robert M. Neer, MD", 
            "investigator_title": "Physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "change in hip bone mineral density", 
                "safety_issue": "No", 
                "time_frame": "study months 30 (phase A), 42 (phase B), 54 (phase C)"
            }, 
            {
                "measure": "change in forearm bone mineral density", 
                "safety_issue": "No", 
                "time_frame": "study months 30 (phase A), 42 (phase B), 54 (phase C)"
            }, 
            {
                "measure": "change in total body bone mineral", 
                "safety_issue": "No", 
                "time_frame": "study months 30 (phase A), 42 (phase B), 54 (phase C)"
            }, 
            {
                "measure": "change in femoral shaft bone mineral density", 
                "safety_issue": "No", 
                "time_frame": "study months 30 (phase A), 42 (phase B), 54 (phase C)"
            }, 
            {
                "measure": "change in serum PINP", 
                "safety_issue": "No", 
                "time_frame": "study months 0-30 (phase A), 30-42 (phase B), 42-54 (phase C)"
            }, 
            {
                "measure": "change in serum osteocalcin", 
                "safety_issue": "No", 
                "time_frame": "study months 0-30 (phase A), 30-42 (phase B), 42-54 (phase C)"
            }, 
            {
                "measure": "change in serum NTX", 
                "safety_issue": "No", 
                "time_frame": "study months 0-30 (phase A), 30-42 (phase B), 42-54 (phase C)"
            }, 
            {
                "measure": "incidence of hypercalcemia", 
                "safety_issue": "Yes", 
                "time_frame": "study months 0-30 (phase A), 30-42 (phase B), 42-54 (phase C)"
            }, 
            {
                "measure": "incidence of hypercalciuria", 
                "safety_issue": "Yes", 
                "time_frame": "study months 0-30 (phase A), 30-42 (phase B), 42-54 (phase C)"
            }, 
            {
                "measure": "incidence of symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "study months 0-30 (phase A), 30-42 (phase B), 42-54 (phase C)"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 1999", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }, 
    "geocoordinates": {
        "Massachusetts General Hospital": "42.358 -71.06"
    }
}